JZileuton Study Group, Acute and chronic effects of a 5-lipoxygenase inhibitor in asthma: a 6-month randomized multicenter trial. Because prescription or pharmacy dispensing of medication may not always equal personal use of the medication,Although this study does not focus on the effectiveness of leukotriene modifiers, some comment on their role in asthma therapy is warranted. Third, these medications are relatively easy to administer in comparison to inhaled agents.  CD The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection. Laviolette  FMHicks From the Department of Medicine (Drs Snyder, Blanc, and Eisner), Divisions of Occupational and Environmental Medicine and Pulmonary and Critical Care Medicine (Drs Blanc and Eisner), and Institute for Health Policy Studies (Drs Katz and Yelin), University of California, San Francisco.

 SSeidenberg  OWood-Dauphinee ; 2003. 

The University of California, San Francisco, Committee on Human Research approved the study. Barnes  PJ Current therapies for asthma: promise and limitations.

 EH Pulmonary and allergy subspecialty care in adults with asthma: treatment, use of services, and health outcomes.  ISummerton  PSampson

 BJ Effects of adding either a leukotriene receptor antagonist or low-dose theophylline to a low or medium dose of inhaled corticosteroid in patients with persistent asthma.

 OJSims

Never ignore professional medical advice in seeking treatment because of something you have read on the WebMD Site. They are not used to treat asthma attacks.

 GC Anti-leukotriene agents compared to inhaled corticosteroids in the management of recurrent and/or chronic asthma in adults and children.

 et al.  SBenner  STBradding

Guyatt  FMHicks Leukotriene modifiers include two types of agents: Leukotriene-receptor antagonists, such as montelukast and zafirlukast, prevent leukotrienes from binding to their receptors Leukotriene synthesis inhibitors, such as zileuton, block the enzyme, 5-lipoxygenase, which is … Lofdahl Eisner

 AJ An evaluation of an asthma quality of life questionnaire as a measure of change in adults with asthma.  TFLeff Montelukast/Beclomethasone Study Group, Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma: a randomized, controlled trial.

 EHBlanc

 MDLieu Liu Dempsey Here, we review the role of leukotrienes in asthma pathogenesis and appropriate uses for leukotriene modifiers in asthma management. They are typically not a first-line treatment.

Leukotriene modifiers are an appropriate long-term controller medication for mild-to-moderate asthma.New therapeutic options for chronic diseases are being developed and introduced at a rapid rate. Israel  MSMcHorney  EHShiboski Controlling for severity-of-asthma score did not appreciably affect these results (data not shown). Leukotrienes are considered more important than prostaglandins as inflammatory agents; they induce bronchoconstriction and mucus production.  CARogers

 ECohn Of the 39 patients who reported leukotriene modifier use at baseline, 27 (69%) continued to report use, and the remaining 12 (31%) had stopped using leukotriene modifiers.We examined the impact of baseline asthma severity on new-onset leukotriene modifier use at follow-up among the 310 patients who indicated no baseline use, controlling for personal characteristics and smoking history (Specialist physician care for asthma was related to the likelihood of new-onset leukotriene modifier use at longitudinal follow-up.  JDube Leukotriene modifiers, a newer drug class, add to the pharmacologic approaches to asthma management.  PJ Current therapies for asthma: promise and limitations.  GBDunn  JMZileuton Clinical Trial Group, Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma: a randomized controlled trial.

The baseline questionnaire ascertained whether patients had used zileuton (Zyflo; Abbott Laboratories, Abbott Park, Ill) and zafirlukast (Accolate; AstraZeneca Pharmaceuticals, Wilmington, Del) during the past 18 months and past 2 weeks.  JEKemp Other Answers On: Small studies, with varying quality of controls, show that treatment of patients with leukotriene receptor antagonists modifies a number of outcome indicators in COPD.  EHShiboski First, unlike corticosteroids, LTMs target a specific pathway of the inflammatory cascade thought to play a significant role in asthma pathogenesis.  MDAckerson  PPEisner

 MBesson Blanc

 PD Risk factors for hospitalization among adults with asthma: the influence of sociodemographic factors and asthma severity. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients.

 OJSims WebMD does not provide medical advice, diagnosis or treatment.  et al.  EJLipworth References  PDCisternas Reiss  GBDunn They are given once a day in the evening.  A Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study.  MSMcHorney Fish

The finding that leukotriene modifier use was more common among adults with greater asthma severity could reflect clinicians' perceived need for treatment alternatives for severe asthma not controlled with conventional medications.  RABernstein  JPLockey  OJFowler For each medication, we listed all trade and generic names. Ware